Progression of macular atrophy after PDT combined with the
COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD

J 2014

Progression of macular atrophy after PDT combined with the COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD

SIN, Martin; Oldřich CHRAPEK; Marta KARHANOVA; Zuzana PRACHAROVA; Katerina LANGOVA et al.

Základní údaje

Originální název

Progression of macular atrophy after PDT combined with the COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD

Autoři

SIN, Martin; Oldřich CHRAPEK; Marta KARHANOVA; Zuzana PRACHAROVA; Katerina LANGOVA a Jiri REHAK

Vydání

Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2014, 1213-8118

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.200

Označené pro přenos do RIV

Klíčová slova anglicky

age-related macular degeneration; cyclooxygenase-2; CD36 metabolic pathway; combination therapy; nabumetone; macula atrophy progression; choroidal atrophy

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 11. 2019 12:57, Mgr. Tereza Miškechová

Anotace

V originále

Aim. To evaluate photodynamic therapy (PDT) combined with the preferential the cyclooxygenase-2 (COX-2) inhibitor, nabumetone in the treatment of the neovascular age-related macular degeneration (ARMD). Methods. A prospective, double-blind, randomized study on 60 patients with subfoveal CNV secondary to ARMD without any previous treatment. Patients were divided into a nabumetone or placebo group. The main endpoints were the change of best-corrected visual acuity (BCVA), central macular thickness (CRT) and number of required PDT treatments. Results. In the nabumetone group, 27 patients (90%) and 28 (93%) in the placebo group completed the follow-up of 12 months. In the nabumetone group, the mean CRT decreased from 332 m (SD 68 m) to 220 m (SD 46 m). In the placebo group, CRT decreased from 331 m (SD 72 m) to 254 m (SD 61 m). The mean BCVA was 0.68 log MAR (SD 0.22 log MAR) in the nabumetone group and 0.62 log MAR (SD 0.23 log MAR) in the placebo group at baseline. This stabilised in the placebo group to 0.66 log MAR (SD 0.33) but deteriorated in the nabumetone group to 0.86 logMAR (SD 0.41 log MAR). There was a significant reduction in the number of required PDTs in the nabumetone group, but significant progression of the RPE atrophy area. Conclusion. Combined PDT with oral intake of the COX-2 inhibitor, nabumetone reduced the number of required PDT retreatments, but worsening BCVA caused by macular atrophy progression. Therefore the combination of the PDT with the nabumetone is not recommended.

Citovat

SIN, Martin; Oldřich CHRAPEK; Marta KARHANOVA; Zuzana PRACHAROVA; Katerina LANGOVA a Jiri REHAK. Progression of macular atrophy after PDT combined with the COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD. Biomedical Papers, Olomouc: Palacky University. Olomouc: Palacky University, 2014, roč. 158, č. 1, s. 138-143. ISSN 1213-8118. Dostupné z: https://doi.org/10.5507/bp.2012.066.

@article{1578696,
   author = {Sin, Martin and Chrapek, Oldřich and Karhanova, Marta and Pracharova, Zuzana and Langova, Katerina and Rehak, Jiri},
   article_location = {Olomouc},
   article_number = {1},
   doi = {https://doi.org/10.5507/bp.2012.066},
   keywords = {age-related macular degeneration; cyclooxygenase-2; CD36 metabolic pathway; combination therapy; nabumetone; macula atrophy progression; choroidal atrophy},
   language = {eng},
   issn = {1213-8118},
   journal = {Biomedical Papers, Olomouc: Palacky University},
   note = {Bez afiliace k MU.},
   title = {Progression of macular atrophy after PDT combined with the COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD},
   volume = {158},
   year = {2014}
}

TY  - JOUR
ID  - 1578696
AU  - Sin, Martin - Chrapek, Oldřich - Karhanova, Marta - Pracharova, Zuzana - Langova, Katerina - Rehak, Jiri
PY  - 2014
TI  - Progression of macular atrophy after PDT combined with the COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD
JF  - Biomedical Papers, Olomouc: Palacky University
VL  - 158
IS  - 1
SP  - 138-143
EP  - 138-143
PB  - Palacky University
SN  - 12138118
N1  - Bez afiliace k MU.
KW  - age-related macular degeneration
KW  - cyclooxygenase-2
KW  - CD36 metabolic pathway
KW  - combination therapy
KW  - nabumetone
KW  - macula atrophy progression
KW  - choroidal atrophy
N2  - Aim. To evaluate photodynamic therapy (PDT) combined with the preferential the cyclooxygenase-2 (COX-2) inhibitor, nabumetone in the treatment of the neovascular age-related macular degeneration (ARMD). Methods. A prospective, double-blind, randomized study on 60 patients with subfoveal CNV secondary to ARMD without any previous treatment. Patients were divided into a nabumetone or placebo group. The main endpoints were the change of best-corrected visual acuity (BCVA), central macular thickness (CRT) and number of required PDT treatments. Results. In the nabumetone group, 27 patients (90%) and 28 (93%) in the placebo group completed the follow-up of 12 months. In the nabumetone group, the mean CRT decreased from 332 m (SD 68 m) to 220 m (SD 46 m). In the placebo group, CRT decreased from 331 m (SD 72 m) to 254 m (SD 61 m). The mean BCVA was 0.68 log MAR (SD 0.22 log MAR) in the nabumetone group and 0.62 log MAR (SD 0.23 log MAR) in the placebo group at baseline. This stabilised in the placebo group to 0.66 log MAR (SD 0.33) but deteriorated in the nabumetone group to 0.86 logMAR (SD 0.41 log MAR). There was a significant reduction in the number of required PDTs in the nabumetone group, but significant progression of the RPE atrophy area. Conclusion. Combined PDT with oral intake of the COX-2 inhibitor, nabumetone reduced the number of required PDT retreatments, but worsening BCVA caused by macular atrophy progression. Therefore the combination of the PDT with the nabumetone is not recommended.
ER  -

SIN, Martin; Oldřich CHRAPEK; Marta KARHANOVA; Zuzana PRACHAROVA; Katerina LANGOVA a Jiri REHAK. Progression of macular atrophy after PDT combined with the COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD. \textit{Biomedical Papers, Olomouc: Palacky University}. Olomouc: Palacky University, 2014, roč.~158, č.~1, s.~138-143. ISSN~1213-8118. Dostupné z: https://doi.org/10.5507/bp.2012.066.

Přehled o publikaci